newsfilter
← Latest News
GlobeNewswire·

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

  • Fractyl Health will host a virtual Commercial Strategy Day on September 1, 2026, at 11:00 AM ET to discuss the go-to-market strategy for Revita.
  • The event follows positive one-year REMAIN-1 Midpoint Cohort data showing Revita-treated participants maintained approximately 84% of GLP-1-induced weight loss compared to 46% in sham participants.
  • Revita is designed as a one-time procedural off-ramp for the estimated 30 million U.S. adults currently on GLP-1 therapy.
  • Management will discuss market opportunities, reimbursement paths, and an anticipated late Q4 2026 FDA De Novo application submission.
  • An early Q4 2026 six-month topline readout for the REMAIN-1 Pivotal Cohort is expected.
  • A live Q&A session will follow the presentations, with a webcast available on Fractyl's investor relations website for 90 days.
  • Fractyl is transitioning from late-stage clinical development to commercial readiness with its lead candidate Revita, which holds FDA Breakthrough Device designation for weight maintenance post-GLP-1 discontinuation.
  • The company also advances Rejuva, an AAV-based gene therapy platform with lead candidate RJVA-001 entering first-in-human studies.